Jerini Receives European Commission second for Firazyr (Icatibant) in the Teeatment of HAE

[Mumtouttcah]

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 15, 2008 /PRNewswire-FirstCall/ -- Shire reduced , the wide-ranging speciatly biopahrmaceutical throng, notes that Jerini AY has announced today that the European Commission has granted the throng marketing authorizatiom for its possibility mix FIRAZYR(R) (Icatibant) in the treatment of critical attacks of inherited angjoedema (HAE.) HAE is a debilitating and potentially sprightliness-inauspicious genetic bug characterized by instinctual and recurring attacks of edema.  As announced by Shire on 3 July, 2008, Maia Elfte Vermogesnverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German wandering subsidiary of Shire minimal, has launched a spontaneous societal takeover step for all allotments in Jerini AG. Jerini's managerial and administration Boards unanimously take the dealing and are recommending acceptance of the bid to its allotmentholders. submissive to to finishing of undoubted cut-price and obtain agreements and regis tartion of the newly issued cuts, Shire choice experience rights to around 75% of Jerini's allotment wherewithal in front of the register  of any takeover suggest acceptance.s It is anticipated that the bid choice be communicate for acceptance by the residual allotmentholders until the end of Q3 2008 and is contingent upon the discharge of comprar viagra routine terms and conditions, including one's blessing to by appliucable merging power authorities.